Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 18/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21250161 | 0.82 | SMN1; SMN2 (0.65) | CFTRMEN1KMT2AKDM4ENPC1 | |
| SCHEMBL21260747 | 0.81 | CFTR (0.41) | CFTRALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL21260703 | 0.78 | CFTR (0.54) | CFTR | |
| SCHEMBL20468190 | 0.78 | CFTR (0.69) | CFTR | |
| SCHEMBL21018758 | 0.76 | CFTR (0.55) | CFTR | |
| SCHEMBL21248056 | 0.72 | CFTR (0.59) | CFTRALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL22680997 | 0.71 | MAPT (0.44) | MEN1KMT2AKDM4ENPC1ALDH1A1 | |
| SCHEMBL22686816 | 0.70 | CFTR (0.50) | CFTRALDH1A1 | |
| SCHEMBL21247367 | 0.70 | CFTR (0.52) | CFTRMEN1KMT2AKDM4ENPC1 | |
| SCHEMBL20468243 | 0.69 | CFTR (0.53) | CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200369682-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369682-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | FTH1, SLC40A1, FECH | CFTR 2739/4885MEN1 3538/4885KMT2A 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.